Pharmaceutical Technology

MARCH 22, 2023

To learn more about the 3M TM Harvest RC Chromatographic Clarifier and the efficiencies achievable in biopharma manufacturing, download the specially commissioned white paper on this page.

Documentation 52

Documentation Communication 52

Pharmaceutical Technology

JANUARY 20, 2023

To learn more about the ways that the 3MTM Harvest RC Chromatographic Clarifier can increase efficiencies in the production of mAb therapies, download this specially commissioned white paper.

Documentation 52

Documentation Communication 52

pharmaphorum

OCTOBER 20, 2020

Documenting the change in pharma’s engagement of HCPs is one thing – predicting where channel mix goes in the future, the most important question, is quite another. The UK is also unique compared to other countries as remote detailing has risen and continues at close to peak levels.

Pharmaceutical Companies 122

Pharmaceutical Companies Pharmaceutical Companies Documentation Communication 122

pharmaphorum

FEBRUARY 24, 2022

Unlike many of its predecessors, then, this document is not merely an exercise in raising awareness. BIVDA really hope that the white paper will help inform UK policy makers and give them areas to focus on which we, as a coalition, see as critical to start moving this issue forward.”. Clear objectives.

Documentation 52

Documentation Vaccines 52

The FDA Law Blog

JUNE 19, 2023

And regulating LDTs through guidance documents is vulnerable to legal challenge on procedural grounds. See , e.g. , ACLA White Paper on LDTs here. Rulemaking avoids the twin problems of dependency on action by Congress and the legal weakness of imposing substantive legal requirements through guidance.

FDA 56

FDA Documentation 56

Pharmaceutical Technology

OCTOBER 28, 2022

QbD principles are woven into regulatory guidance documents, primarily guidances Q8 to Q11 of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). For more information on this, please download our white paper. For more information, please download our white paper.

Vaccines 52

Vaccines Documentation FDA 52

ISPE

JULY 19, 2023

™” is becoming an increasingly rhetorical one, particularly in view of the growing momentum in the pharmaceutical industry and in various statements and white papers from key regulatory agencies. Is the vendors’ documentation complete in order to assess GxP risks and GxP compliance? The upcoming Pharma 4.0™

Documentation 98

Documentation FDA Labelling Communication 98

The FDA Law Blog

OCTOBER 10, 2022

Javitt — On September 28, 2022, the FDA issued the long anticipated final Clinical Decision Support Software Guidance (CDS Guidance), which replaces the revised draft guidance document from 2019.

FDA 52

FDA Labelling Documentation Communication 52

ISPE

NOVEMBER 1, 2022

OPQ is engaged in various steps to develop QMM, including a quality rating system; activities such as stakeholder meetings and a white paper released in April on the importance of QMM and an upcoming advisory committee meeting are further steps toward that goal.

FDA 98

FDA Insurance Chemotherapy Documentation 98

ISPE

JULY 6, 2023

This document is approved by the firm’s board of directors and sets the tone for risk-taking at the company by key risks and setting risk tolerances for how much risk the board is willing to take across all business activities. This document catalogs and summarizes the various risks to the company. March 2023. Published 2022.

Insurance 52

Insurance Documentation Pharmaceutical Companies Pharmaceutical Companies 52

ISPE

FEBRUARY 1, 2023

This shift in approach to validation aims to realign effort to planning and preparation first, then defining the testing to be performed, and finally test execution and documentation. Download White Paper To download this white paper, complete the form below.

Documentation 98

Documentation Communication 98

ISPE

MARCH 29, 2023

Concept Paper: M4Q(R2) Common Technical Document on Quality Guideline.” Ultimately, the summary was not adopted during the QbD pilot, but was reintroduced in 2014 when a Pharmaceutical Research and Manufacturers of America (PhRMA) team prepared a white paper describing the content and format of an improved Module 2.

Documentation 52

Documentation Dosage Packaging Communication 52

ISPE

MARCH 29, 2023

Concept Paper: M4Q(R2) Common Technical Document on Quality Guideline.” Ultimately, the summary was not adopted during the QbD pilot, but was reintroduced in 2014 when a Pharmaceutical Research and Manufacturers of America (PhRMA) team prepared a white paper describing the content and format of an improved Module 2.

Documentation 52

Documentation Dosage Packaging Communication 52

ISPE

JULY 1, 2023

Introducing EU Annex 1: Understanding the Newest Regulatory Requirements Trudy Patterson Sat, 07/01/2023 - 06:00 White Paper — Sponsored Content Introducing EU Annex 1: Understanding the Newest Regulatory Requirements 1 July 2023 As its title implies, Annex 1 is the European guidance document for good manufacturing practices of medicinal products.

Documentation 52

Documentation Communication 52

ISPE

JULY 1, 2023

Documentation has experienced the same incredible advancements and that has significant impacts on industries that are dependent on it, such as the life sciences industry, consumer packaged goods manufacturers, and businesses involved in other highly regulated fields. Download White Paper To download this white paper, complete the form below.

Communication 52

Communication Packaging Documentation 52

ISPE

AUGUST 29, 2022

For changes requiring approval before implementation, once the necessary information has been submitted across regions, each health authority must review the data package and documentation based on local requirements. laboratory notebooks, batch records, and technical reports) to submission documents (e.g., doi:10.1016/j.xphs.2021.09.046.

Documentation 52

Documentation FDA Communication Packaging 52

ISPE

SEPTEMBER 11, 2023

Subsequently, the new data is authored into Module 3 (Quality) of the Common Technical Document and submitted separately to multiple health authorities worldwide for approval. EFPIA White Paper on CMC Development, Manufacture and Supply of Pandemic COVID-19 Therapies and Vaccines.” EMA/CHMP/BWP/187162/2018. 22 March 2018.

Health and Personal Care Stores 52

Health and Personal Care Stores Vaccines Packaging Documentation 52

ISPE

NOVEMBER 3, 2022

A white paper on regulatory development for low- to middle-income countries, international collaboration on methods for producing gene therapies, and public/private partnerships to support therapies for extremely rare disorders are other steps to consider. Convergence is a goal in revisions of ICH, he said.

Communication 98

Communication FDA Documentation Vaccines 98

The FDA Law Blog

JANUARY 24, 2024

Fast-forward to March 2023, when The White House OSTP issued a document per Executive Order 14081, titled “ Bold Goals for U.S. Biotechnology and Biomanufacturing; Harnessing Research and Development to Further Societal Goals.”

Documentation 69

Documentation 69

ISPE

JULY 5, 2023

13 An FDA-authored paper indicating support for the implementation of CM using science- and risk-based approaches followed soon thereafter. To this end, the FDA will conduct a workshop that includes industry and public feedback and publish a draft strategy document for public comment on innovative manufacturing technologies.

FDA 52

FDA Dosage Documentation Pharmaceutical Companies 52

Pharmaceutical Technology

JANUARY 6, 2023

According to the legal documents , the plaintiffs accused the companies of “violating federal antitrust laws, alleging “per se” and “rule of reason” violations”. Gilenya is an oral medication for multiple sclerosis.

Documentation 97

Documentation FDA Hospitals Dosage 97

Pharmaceutical Technology

APRIL 16, 2023

To learn more, download the document below. model, download this white paper. Through its Maggie family of autoinjectors, SHL is working with its partners to advance the device development side of combination products, together gaining key competitive edges in this burgeoning subcutaneous drug delivery market. References 1.

Documentation 52

Documentation Communication Hospitals 52

Pharmaceutical Technology

DECEMBER 15, 2022

In addition, several pieces of documentation will be required to support the API qualification, e.g. pharmacopeial compliance. It is also essential to evaluate the reliability of the company supplying the ingredient: do they provide sufficient communication and documentation?

Documentation 52

Documentation Compounding Communication Pharmaceutical Companies 52

Pharmaceutical Technology

MAY 4, 2023

To find out more about Pall’s specialist filters and the services available in water safety, download the white paper on this page. This document will explain the dangers associated with waterborne bacteria and the importance of a Holistic Water Safety Plan.

Hospitals 52

Hospitals Documentation Communication Immunization 52

Pharmaceutical Technology

FEBRUARY 16, 2023

The document contains detailed information on the suppliers and their product offerings, alongside contact details to aid your purchasing or hiring decision.

Documentation 52

Documentation Communication 52

Pharmaceutical Technology

DECEMBER 13, 2022

Integrated logistics and quality data is documented automatically, and operators can spend less time chasing status, progress and performance data from multiple sources. Effective data sharing can enable the automation of quality documentation, release processes and stability budgets. Challenge 3: Minimising waste.

Vaccines 52

Vaccines Communication Documentation 52

Pharmaceutical Technology

NOVEMBER 28, 2022

To learn more about the development and partnership opportunities for businesses within Scotland’s health sector, download the document on this page. Free Whitepaper. Precision Medicine: Streamlining Treatments and Drug Development.

Packaging 52

Packaging Hospitals Medical Schools Documentation 52

Pharmaceutical Technology

MARCH 2, 2023

While not binding, the document covers the regulatory and scientific considerations needed for the development and implementation of continuous manufacturing in pharma, and the guidelines are meant for both new and pre-existing products. Funding was also given to companies that would bolster US-based production of critical medicines.

FDA 84

FDA Documentation Communication 84